Drug Trial Radar · NCT07830758
Resmetirom in Patients With MASH and HFpEF
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.
Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
ResmetiromDrug
Resmetirom (80 mg or 100 mg orally once daily based on body weight)
PlaceboDrug
Matching placebo orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: From first dose through End of Study follow-up (28 days after last dose)
- Incidence of treatment-emergent serious adverse events (SAES)Time frame: From first dose through End of Study follow-up (28 days after last dose)
- Change from baseline in physical examination findings assessed by investigator physical examinationTime frame: Baseline to Week 24
- Change from baseline in body temperatureTime frame: Baseline to Week 24
- Change from baseline resting heart rateTime frame: Baseline to Week 24
- Change from baseline in respiratory rateTime frame: Baseline to Week 24
- Change from baseline in seated systolic blood pressureTime frame: Baseline to Week 24
- Change from baseline in seated diastolic blood pressureTime frame: Baseline to Week 24
- Change from baseline in PR interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
- Change from baseline in QRS interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
- Change from baseline in heart rate on 12-lead ECG in beats per minute (bpm)Time frame: Baseline to Week 24
- Change from baseline in RR interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
- Change from baseline in QT interval on 12-lead ECG in milliseconds (ms)Time frame: Baseline to Week 24
- Change from baseline in QT interval corrected using Bazett's formula (QTcB) in milliseconds (ms)Time frame: Baseline to Week 24
- Change from baseline in QT interval corrected using Fridericia's formula (QTcF) in milliseconds (ms)Time frame: Baseline to Week 24
- Number of participants with clinically significant abnormalities in hematology laboratory parametersTime frame: Baseline to Week 24
- Number of participants with clinically significant abnormalities in blood chemistry laboratory parametersTime frame: Baseline to Week 24
- Number of participants with clinically significant abnormalities in urinalysis parametersTime frame: Baseline to Week 24
- Percent change from baseline in liver fat content measured by MRI-Proton Density Fat Fraction (MRI-PDFF)Time frame: Baseline to Week 24
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Arizona Clinical Trials
Peoria, Arizona · Recruiting
FOMAT - Clinicas Mi Salud
Oxnard, California · Recruiting
Covenant Metabolic Specialist
Fort Myers, Florida · Recruiting
Covenant Metabolic Specialist
Riverview, Florida · Recruiting
Covenant Metabolic Specialist
University Park, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.